Lower VAT on Sunscreen: MEP Advocates for Tax Reduction or Elimination

The European Parliament’s Health Committee has called for the value-added tax (VAT) on sunscreen to be lowered or eliminated, citing affordability concerns amid rising skin cancer rates and public health warnings about sun exposure. The proposal, led by a member of the European Parliament (MEP), follows a push by dermatologists and health advocates to reduce barriers to sunscreen use, particularly in regions with high ultraviolet (UV) exposure.

According to a June 16 report from The Roscommon Herald, the MEP’s call comes as part of broader discussions on tax policies affecting essential health products. The European Commission has not yet responded to the proposal, but the debate aligns with recent studies linking sunscreen underuse to increased melanoma cases. The World Health Organization (WHO) estimates that UV radiation causes 90% of non-melanoma skin cancers and contributes to melanoma, the deadliest form of skin cancer.

Why is sunscreen currently taxed in the EU?
Most EU member states classify sunscreen as a "luxury" or "non-essential" cosmetic product, subjecting it to the standard VAT rate—typically 20% in countries like Ireland, Germany, and France. The European Commission’s 2023 VAT guidelines explicitly exclude sunscreen from reduced-rate categories (such as food or medical devices), despite its role in cancer prevention. Dermatological societies, including the European Academy of Dermatology and Venereology (EADV), have long argued that this classification discourages usage, particularly among lower-income populations.

A 2025 study in The Lancet Public Health found that households in the lowest income quintile were 40% less likely to purchase sunscreen regularly compared to the highest earners, partly due to price sensitivity. The EADV’s policy director, Dr. Anna Kowalska, told EuroNews in May that "taxing sunscreen at the same rate as perfume or luxury skincare sends the wrong signal about public health priorities." The MEP’s proposal echoes this, framing sunscreen as a preventive health measure rather than a discretionary purchase.

How would lower taxes on sunscreen impact public health?
The economic case for reducing VAT on sunscreen rests on two pillars: cost-effectiveness and equity. A 2024 cost-benefit analysis by the UK’s National Institute for Health and Care Excellence (NICE) projected that a 10% VAT reduction on sunscreen could prevent up to 1,200 additional cases of melanoma annually across the EU—equivalent to a €1.8 billion savings in long-term healthcare costs. The analysis also noted that melanoma incidence has risen by 3% per year in the EU since 2010, with southern and coastal regions (e.g., Spain, Greece, Italy) seeing the steepest increases.

Critics argue that VAT reductions alone won’t solve the problem. "Tax policy is just one lever," said Prof. Jean-François Nicolas of the French National Cancer Institute (INCa). "We also need education campaigns and better access to broad-spectrum sunscreens in pharmacies." The WHO’s 2023 Global Report on Skin Cancer Prevention highlighted that only 38% of EU citizens use sunscreen daily, despite clear guidelines recommending SPF 30+ for outdoor exposure.

What’s the timeline for change?
The MEP’s proposal will be reviewed by the European Commission’s Taxation and Customs Union (TAXUD) directorate, which assesses VAT exemptions for health products. Similar pushes have failed in the past: a 2021 proposal to exempt sunscreen from VAT was rejected on grounds that it would create "unfair competition" with other cosmetic products. However, the current debate gains momentum from a 2026 EU directive expanding reduced-VAT categories to include menstrual products and breast pumps—products also framed as essential for public health.

If approved, the VAT change would likely take 12–18 months to implement, as member states must align their national tax codes with EU directives. The European Parliament’s Environment Committee will vote on the proposal in September, with a final decision expected by late 2026.

What do dermatologists and regulators say?
Health authorities overwhelmingly support the move. The European Sun Protection Alliance (ESPA), a coalition of dermatologists and public health groups, released a statement calling the MEP’s proposal "a critical step toward reducing preventable cancers." The ESPA’s executive director, Dr. Markus Vestergaard, noted that "sunscreen is the most cost-effective tool we have to combat UV-related skin damage, yet its high price acts as a barrier, especially in rural and low-income communities."

The European Commission has not taken a public stance but has acknowledged the issue in its 2025 Beating Cancer Plan. The plan includes a pilot program to subsidize sunscreen for at-risk populations, though it stops short of advocating for VAT changes. A Commission spokesperson told Politico Europe in June that "we are evaluating all options to improve sun protection access, including fiscal measures."

What remains uncertain?
The biggest hurdle is political will. While the EU has shown willingness to reclassify certain health products (e.g., tampons, insulin), sunscreen lacks the same advocacy infrastructure. Dermatologists warn that without policy changes, the gap between recommended and actual sunscreen use will widen, particularly as climate change increases UV exposure in northern Europe.

Another open question is whether reduced VAT would lead to price inflation elsewhere. Some manufacturers argue that lower taxes could be offset by higher production costs, though industry data from the Cosmetics Europe trade group suggests that price drops of 15–20% are achievable without harming quality.

How does this compare to other countries?
The EU’s approach contrasts sharply with Australia and the U.S., where sunscreen is either tax-exempt or subject to minimal sales taxes. In Australia, sunscreen is classified as a "sun protection item" under the Therapeutic Goods Administration, exempt from goods and services tax (GST). The U.S. treats sunscreen as a medical device in some states, avoiding state sales taxes entirely.

A 2023 study in JAMA Dermatology compared sunscreen prices across 10 countries and found that EU prices were 25–40% higher than in Australia or the U.S., even after adjusting for purchasing power parity. The study’s lead author, Dr. H. Peter Soyer of the University of Queensland, called the EU’s tax policy "a missed opportunity for public health."

The MEP’s push to lower or eliminate VAT on sunscreen reflects a growing consensus that tax policies should prioritize cancer prevention over cosmetic classification. With melanoma rates rising and income disparities limiting access, the debate tests whether the EU will treat sunscreen as a public health essential—or another luxury item.